Claritas Pharmaceuticals, Inc. engages in the development of next generation cannabinoid therapeutics. The company is headquartered in San Rafael California, California. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The firm has leased a laboratory, office, and archival space in Beverly, Massachusetts.
Leveraging in-depth analyst evaluations, we have synthesized critical insights from expert assessments to deliver a robust outlook for CLAZF. Our analysts highlight strong fundamentals and favorable market sentiment, positioning CLAZF for significant upside potential in the near term. Based on this comprehensive expert analysis, we maintain a highly optimistic view of this stock. Our conclusion: CLAZF is a Strong Buy candidate.
CLAZF stock price ended at $0 on 火曜日, after rising NaN%
On the latest trading day Dec 16, 2025, the stock price of CLAZF rose by NaN%, climbing from $0.00 to $0.00. Throughout the session, the stock experienced a volatility of NaN%, with prices fluctuating between a daily low of $0.00 and a high of $0.00. Alongside this price increase, trading volume also rose by 125 shares, reflecting strong market interest that may signal continued bullish momentum in the near term. In total, 500 shares were traded, amounting to a market value of approximately --.